Vilobelimab and Breastfeeding

Summary of use during lactation

No information is available about vilobelimab during breastfeeding. Because vilobelimab is a large protein molecule with a molecular weight of about 149,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] The manufacturer recommends that breastfeeding be discontinued during vilobelimab use. The half-life of vilobelimab is about 4 days, so it should be mostly eliminated about 2 weeks after the last dose. If the mother is at least 2 weeks postpartum the transfer into milk may be minimized.[3]

Drug levels in milk and infant serum

Maternal Levels. Relevant published information was not found as of the revision date. Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

References

1. Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003
2. Anderson PO. Monoclonal antibodies during breastfeeding. Breastfeed Med 2021;16:591-3.33956488 PubMed
3. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol 2023;22:350-66.36931808 PubMed